Terms: = Breast cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF AND Treatment
1209 results:
1. Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer.
Zhao Y; Wucherpfennig KW
Curr Opin Oncol; 2024 May; 36(3):136-142. PubMed ID: 38573202
[TBL] [Abstract] [Full Text] [Related]
2. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment.
He Y; Yu Q; Ma X; Lv D; Wang H; Qiu W; Chen XF; Jiao Y; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118075. PubMed ID: 38513779
[TBL] [Abstract] [Full Text] [Related]
3. Zirconium-containing nanoscale coordination polymers for positron emission tomography and fluorescence-guided cargo delivery to triple-negative breast tumors.
Li YP; Pan ZW; Jiang YJ; Peng YY; Cai T; Hong H; Wang XF
Acta Biomater; 2024 Apr; 179():313-324. PubMed ID: 38490483
[TBL] [Abstract] [Full Text] [Related]
4. Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS-method development, validation, comparison of four sample matrices, and proof of concept.
Jacobs CM; Radosa JC; Wagmann L; Zimmermann JSM; Kaya AC; Aygün A; Edel T; Stotz L; Ismaeil M; Solomayer EF; Meyer MR
Anal Bioanal Chem; 2024 May; 416(12):2969-2981. PubMed ID: 38488952
[TBL] [Abstract] [Full Text] [Related]
5. treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
6. Addressing Residual Disease in HER2-Positive and Triple-Negative breast cancer: What Is Next?
Schlam I; Dower J; Lynce F
Curr Oncol Rep; 2024 Apr; 26(4):336-345. PubMed ID: 38393609
[TBL] [Abstract] [Full Text] [Related]
7. Integrating serum pharmacochemistry and network pharmacology to explore the molecular mechanisms of Acanthopanax senticosus (Rupr. & Maxim.) Harms on attenuating doxorubicin-induced myocardial injury.
Zhang X; Zhang Q; Yu M; Zhang Y; He T; Qiu Z; Qiu Y; Wang W
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117349. PubMed ID: 38380572
[TBL] [Abstract] [Full Text] [Related]
8. EXPRESSION PROFILE OF miR-145, -182, -21, -27a, -29b, and -34a IN breast cancer PATIENTS OF YOUNG AGE.
Chekhun V; Borikun T; Mushii O; Zadvornyi T; Martyniuk О; Kashuba E; Bazas V; Hrybach S; Krotevych M; Lyalkin S; Lukianova N
Exp Oncol; 2024 Feb; 45(4):421-431. PubMed ID: 38328848
[TBL] [Abstract] [Full Text] [Related]
9. ASSESSMENT OF CIRCULATING miRNA LEVELS IN breast cancer PATIENTS DEPENDING ON CLINICAL CHARACTERISTICS AND CHEMOTHERAPY.
Harashchenko О
Exp Oncol; 2024 Feb; 45(4):451-456. PubMed ID: 38328845
[TBL] [Abstract] [Full Text] [Related]
10. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
11. Systemic platelet inhibition with localized chemotherapy by an injectable ROS-scavenging gel against postsurgical breast cancer recurrence and metastasis.
Gui J; Zhu Y; Chen X; Gong T; Zhang Z; Yu R; Fu Y
Acta Biomater; 2024 Mar; 177():388-399. PubMed ID: 38307476
[TBL] [Abstract] [Full Text] [Related]
12. Dye-augmented bandgap engineering of a degradable cascade nanoreactor for tumor immune microenvironment-enhanced dynamic phototherapy of breast cancer.
He Z; Du J; Wang Q; Chen G; Li X; Zhang Z; Wang S; Jing W; Miao Q; Li Y; Miao Y; Wu J
Acta Biomater; 2024 Mar; 176():390-404. PubMed ID: 38244657
[TBL] [Abstract] [Full Text] [Related]
13. PARP Inhibitors in breast cancer: a Short Communication.
Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
[TBL] [Abstract] [Full Text] [Related]
14. Male breast cancer: a Review on Diagnosis, treatment, and Survivorship.
Bhardwaj PV; Gupta S; Elyash A; Teplinsky E
Curr Oncol Rep; 2024 Jan; 26(1):34-45. PubMed ID: 38224426
[TBL] [Abstract] [Full Text] [Related]
15. Immunotherapy for Early-Stage Triple Negative breast cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract] [Full Text] [Related]
16. Updates in the treatment of HR+HER2- breast cancer.
Baclig NV; McCann KE
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):57-63. PubMed ID: 38170552
[TBL] [Abstract] [Full Text] [Related]
17. New strategies for the management of triple-negative breast cancer.
Riaz F
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):40-44. PubMed ID: 38170551
[TBL] [Abstract] [Full Text] [Related]
18. Managing chronic pain after breast cancer treatments: are web-based interventions the future?
Hartup S; Briggs M
Curr Opin Support Palliat Care; 2024 Mar; 18(1):47-54. PubMed ID: 38170201
[TBL] [Abstract] [Full Text] [Related]
19. cancer survivor late-effects, chronic health problems after cancer treatment: what's the evidence from population and registry data and where are the gaps?
Faithfull S; Greenfield D
Curr Opin Support Palliat Care; 2024 Mar; 18(1):55-64. PubMed ID: 38170192
[TBL] [Abstract] [Full Text] [Related]
20. Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis.
Gong G; Ganesan K; Liu Y; Huang Y; Luo Y; Wang X; Zhang Z; Zheng Y
J Ethnopharmacol; 2024 Apr; 323():117655. PubMed ID: 38158099
[TBL] [Abstract] [Full Text] [Related]
[Next]
